BR112022019687A2 - Conjugados para responsividade seletiva a dióis vicinais - Google Patents

Conjugados para responsividade seletiva a dióis vicinais

Info

Publication number
BR112022019687A2
BR112022019687A2 BR112022019687A BR112022019687A BR112022019687A2 BR 112022019687 A2 BR112022019687 A2 BR 112022019687A2 BR 112022019687 A BR112022019687 A BR 112022019687A BR 112022019687 A BR112022019687 A BR 112022019687A BR 112022019687 A2 BR112022019687 A2 BR 112022019687A2
Authority
BR
Brazil
Prior art keywords
vicinal
diols
diol
sensors
responsibility
Prior art date
Application number
BR112022019687A
Other languages
English (en)
Inventor
Mahdavi Alborz
Kelly Spencer Ryan
Joseph Steele Jack
Liang Jingxin
Ekram Anwar Shaker Mirna
chen Diao
Mali Sachitanand
Original Assignee
Protomer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protomer Tech Inc filed Critical Protomer Tech Inc
Publication of BR112022019687A2 publication Critical patent/BR112022019687A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

CONJUGADOS PARA RESPONSIVIDADE SELETIVA A DIÓIS VICINAIS. A presente invenção refere se a sensores que podem se ligar seletivamente a dióis vicinais específicos na presença de outros dióis. Esses compostos sensores boronados responsivos a diol vicinal podem detectar níveis de dióis vicinais específicos e responder a essas moléculas no corpo. Em certas modalidades, o diol vicinal é um diol cis, por exemplo, uma hexose, tal como glicose. Em certas modalidades, os sensores são conjugados a uma substância medicamentosa, e os sensores podem alterar as características biofísicas, a farmacocinética e/ou a atividade da substância medicamentosa em resposta ao diol vicinal. A substância medicamentosa pode ser ou incluir um polipeptídeo, como uma insulina, um peptídeo endócrino ou incretina humano, ou um análogo do mesmo e pode conter um ou mais aminoácidos modificados que contêm um sensor responsivo a diol vicinal.
BR112022019687A 2020-03-31 2021-03-31 Conjugados para responsividade seletiva a dióis vicinais BR112022019687A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002662P 2020-03-31 2020-03-31
PCT/US2021/025261 WO2021202802A1 (en) 2020-03-31 2021-03-31 Conjugates for selective responsiveness to vicinal diols

Publications (1)

Publication Number Publication Date
BR112022019687A2 true BR112022019687A2 (pt) 2022-12-20

Family

ID=75588297

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019687A BR112022019687A2 (pt) 2020-03-31 2021-03-31 Conjugados para responsividade seletiva a dióis vicinais

Country Status (17)

Country Link
US (1) US20230134116A1 (pt)
EP (1) EP4126058A1 (pt)
JP (1) JP2023520049A (pt)
KR (1) KR20220161422A (pt)
CN (1) CN115843257A (pt)
AU (1) AU2021247169A1 (pt)
BR (1) BR112022019687A2 (pt)
CA (1) CA3173417A1 (pt)
CL (1) CL2022002662A1 (pt)
CO (1) CO2022014157A2 (pt)
CR (1) CR20220555A (pt)
EC (1) ECSP22076278A (pt)
GB (1) GB2610490A (pt)
IL (1) IL296804A (pt)
MX (1) MX2022012208A (pt)
PE (1) PE20230457A1 (pt)
WO (1) WO2021202802A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198757A1 (en) * 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US906028A (en) 1908-03-27 1908-12-08 Herbert E Jennison Adjustable foot-block for radiators.
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
KR100310122B1 (ko) 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
PE123799A1 (es) 1997-10-24 1999-12-13 Lilly Co Eli Composiciones insolubles de insulina
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
JP2002500196A (ja) 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
AU2002349295A1 (en) * 2001-12-02 2003-06-17 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
JP2007518811A (ja) 2004-01-23 2007-07-12 カリフォルニア インスティチュート オブ テクノロジー 操作されたタンパク質、ならびに作製方法および使用方法
CA2553040A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101252835B1 (ko) 2004-12-22 2013-04-10 암브룩스, 인코포레이티드 아미노아실-ｔＲＮＡ 합성효소의 조성물 및 그것의 용도
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
US20100247433A1 (en) 2005-10-14 2010-09-30 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
JP5808882B2 (ja) 2006-03-03 2015-11-10 カリフォルニア インスティテュート オブ テクノロジー 分子へのアミノ酸の部位特異的な組み込み
EP2581450B1 (en) 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
US9996862B2 (en) 2012-07-23 2018-06-12 @Pay Ip Holdings Llc Point of sale email-based e-commerce
US9867869B2 (en) * 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2015191705A1 (en) 2014-06-10 2015-12-17 California Institute Of Technology Non-canonical insulins and their uses
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
JP7254792B2 (ja) * 2017-11-09 2023-04-10 ノヴォ ノルディスク アー／エス グルコース感受性アルブミン結合誘導体
CN112423741A (zh) * 2018-04-16 2021-02-26 犹他大学研究基金会 葡萄糖反应性胰岛素
TW202112397A (zh) * 2019-03-29 2021-04-01 丹麥商諾佛．儂迪克股份有限公司 葡萄糖敏感型胰島素衍生物
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch

Also Published As

Publication number Publication date
WO2021202802A1 (en) 2021-10-07
CL2022002662A1 (es) 2023-07-21
ECSP22076278A (es) 2022-12-30
CA3173417A1 (en) 2021-10-07
PE20230457A1 (es) 2023-03-10
KR20220161422A (ko) 2022-12-06
AU2021247169A1 (en) 2022-10-20
MX2022012208A (es) 2022-12-15
GB202214274D0 (en) 2022-11-16
GB2610490A (en) 2023-03-08
US20230134116A1 (en) 2023-05-04
CR20220555A (es) 2023-01-23
CO2022014157A2 (es) 2023-03-27
IL296804A (en) 2022-11-01
EP4126058A1 (en) 2023-02-08
JP2023520049A (ja) 2023-05-15
CN115843257A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
BR112022019687A2 (pt) Conjugados para responsividade seletiva a dióis vicinais
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
Porter Jr et al. Cyclophilin D, somehow a master regulator of mitochondrial function
VandenBerg et al. Biologically inspired and chemically derived methods for glucose‐responsive insulin therapy
AR109513A2 (es) Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende
Song et al. Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum
Yu et al. Glucose-fueled peptide assembly: glucagon delivery via enzymatic actuation
Aoyama et al. Inhibition of GTRAP3-18 may increase neuroprotective glutathione (GSH) synthesis
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
BR112014018306A8 (pt) Miméticos de apelina sintéticos para o tratamento de insuficiência cardíaca
Almeida et al. CoaTx-II, a new dimeric Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom with bactericidal potential: Insights into its structure and biological roles
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
BR112012029689A2 (pt) proteína de fusão sequência de polinucleotídeo, célula hospedeira, composição farmacêutica e uso.
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
UY32765A (es) Preparaciones insulinicas de accion lenta
BR112015024659A8 (pt) formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
PE20191836A1 (es) Compuesto de insulina acilada
Chiu et al. Protein disulfide isomerase in thrombosis
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
Bae et al. Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin
BRPI0800085A2 (pt) composição farmacêutica e curativo para tratamento de lesões de pele, bem como uso de sal de cério associado a uma matriz de colágeno
CN104031141A (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
BRPI0914244A2 (pt) Enzima com atividade contra clostridium
Zamuner et al. Selective grafting of protease-resistant adhesive peptides on titanium surfaces
BR112022014119A2 (pt) Administração oral de peptídeos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]